Merck gets FDA nod for delayed-release Noxafil

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

The FDA approves Merck's (MRK -0.1%) 100 mg delayed-release Noxafil tablets.

The product is indicated for "the prophylaxis of invasive Aspergillus and Candida infections." (PR)